N@N

New Data from the Protect II Study to Be Presented in Late Breaking Clinical Trials Session at Society for Cardiovascular Angio

_{//health-fitness.news-articles.net/content/2011/ .. session-at-society-for-cardiovascular-angio.html}
^{Published in Health and Fitness on Monday, April 18th 2011 at 5:36 GMT by Market Wire}  

DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed Inc ]. (NASDAQ: ABMD), a leading provider of [ breakthrough heart support technologies ], today announced that new data from the PROTECT II study will be presented by William Oa™Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine, and principal investigator for the PROTECT II study, during the late-breaking clinical trials session at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore, Maryland.

"As the primary association for interventional cardiologists, SCAI represents the core group of clinicians that treat prophylactic and emergent patients with interventional medicine"

The presentation, aA Prospective Multicenter Randomized Clinical Trial of Intra-aortic Balloon Pump vs Impella for Hemodynamic Support During High Risk PCI: 90 Day Results from PROTECT IIa will be one of four late-breaking clinical trial presentations to be showcased at the meeting. The PROTECT II presentation is scheduled for Friday, May 6 at 12 p.m. ET at the Hilton Baltimore.

PROTECT II was a prospective multicenter randomized clinical trial of Impella versus the intra-aortic balloon pump for hemodynamic support during high risk percutaneous coronary intervention (PCI).

aAs the primary association for interventional cardiologists, SCAI represents the core group of clinicians that treat prophylactic and emergent patients with interventional medicine,a said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. aWe are excited to present the PROTECT II data to these SCAI members who are devoted to enhancing the standard of care for patients in the cath lab.a

SCAI members represent 4,000 adult and congenital interventional cardiologists . Focus areas for SCAI include establishing standards and guidelines for all aspects of cardiac catheterization and angiography, training, credentialing, safety and quality assurance for cardiovascular procedures.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.